US Patent 11026944 Compositions and methods for treating insomnia
Patent 11026944 was granted and assigned to Eisai on June, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+346 characters)
Article
Patent abstract
In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+6 properties)
Infobox
Patent Inventor Names
Gina Pastino0
Margaret Moline0
Nobuo Yoshida0
Nobuya Suzuki0
Yasuhiro Zaima0
Yurie Akimoto0
Edits on 26 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
110269440
Date of Patent
June 8, 2021
0Patent Application Number
168193410
Date Filed
March 16, 2020
0Official Website
Patent Citations
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 12 Feb, 2022
Golden AI
Edits made to:
Infobox (+11 properties)
US Patent 11026944 Compositions and methods for treating insomnia
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11026944
Date of patent
June 8, 2021
Patent application number
16819341
Date Filed
March 16, 2020
Patent citations
Patent primary examiner
Find more entities like US Patent 11026944 Compositions and methods for treating insomnia
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
